家族性地中海热的研究

doi:10.3877/cma.j.issn.1673-5250.2019.06.002

中华妇幼临床医学杂志(电子版) ›› 2019, Vol. 15 ›› Issue (06) : 612 -617. doi: 10.3877/cma.j.issn.1673-5250.2019.06.002

所属专题：文献；

专题论坛

家族性地中海热的研究

李雪¹, 舒敏¹^,^†(

), 邓建军¹, 李银月¹

^1. 四川大学华西第二医院儿科、出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041

收稿日期:2019-06-02 修回日期:2019-10-17 出版日期:2019-12-01
通信作者: 舒敏

Current research status of familial Mediterranean fever

Xue Li¹, Min Shu¹^,^†(), Jianjun Deng¹, Yinyue Li¹

^1. Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Received:2019-06-02 Revised:2019-10-17 Published:2019-12-01
Corresponding author: Min Shu
About author:
Corresponding author: Shu Min, Email: suemin2005@163.com
Supported by:
Scientific Research Project of Science and Technology Department of Sichuan Province(2017JY275)

全文 ( ) 下载PDF ( ) 导出引用

家族性地中海热(FMF)，是一种与MEFV基因突变有关的常染色体隐性遗传性自身炎症性疾病(AID)。FMF患者主要表现为反复发作的自限性发热和多种浆膜炎，包括腹膜炎、胸膜炎、心包炎及关节炎等。FMF主要见于阿拉伯人、土耳其人、犹太人和伊朗人等地中海血统的4大种族人群。近年文献报道，在其他种族人群中亦发现FMF患者。在中国，也陆续在成年人及儿童中发现FMF患者。引起发热症状的疾病众多，对于反复周期性发热患儿，除考虑内分泌疾病、免疫性疾病外，还应警惕FMF可能。目前对于FMF的有效治疗药物是秋水仙碱。关于FMF诊断标准与治疗的研究，大多针对成年FMF患者。笔者拟总结儿童FMF的诊断标准及治疗药物剂量的研究现状，并就FMF的发病机制、临床表现、分型、一般实验室检查，以及基因突变类型及其检测、诊断标准、治疗结果等最新研究进展进行阐述，旨在为儿科医师提供该病的诊断及治疗依据。

关键词: 家族性地中海热, 基因，隐性, 染色体障碍, 常染色体隐性遗传疾病, 遗传性自身炎症性疾病, 基因测定, 儿童

Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder (AID) associated with mutations in MEVF gene. FMF patients are characterized by recurrent self-limited fever and multiple hydrohymenitis, such as peritonitis, pleurisy, pericarditis, arthritis, etc.. FMF is common in the Arab, Turkish, Jewish and Iranian Mediterranean races, but it has been gradually found in other races in recent years. For example, in the past few years, FMF patients have been found in adults and children in Chinese. There are many diseases causing fever. For children with recurrent periodic fever, besides considering endocrine diseases and immune diseases, FMF should also be considered. The current effective drug for FMF is colchicine. At present, most of the studies on FMF are aimed at adult patients, including diagnostic criteria, treatment and so on. This article will summarize diagnostic criteria and doses of therapeutic drugs for children with FMF, and elaborate the pathogenesis, clinical manifestation, classification and general laboratory examinations of FMF, the types of gene mutation and its detection, diagnostic criteria and treatment results in the latest research progresses, aiming to provide a basis for early diagnosis and early treatment of this disease.

Key words: Familial Mediterranean fever, Genes, recessive, Chromosome disorders, Autosomal recessive genetic disease, Hereditary autoinflammatory diseases, Genetic testing, Child

表1 儿童家族性地中海热的新诊断标准中的主要临床症状及其体征

临床症状	临床体征
发热	持续时间为6～72 h，体温>38 ℃，发作次数≥3次
腹痛	持续时间为6～72 h，发作次数≥3次
胸痛	持续时间为6～72 h，发作次数≥3次
关节炎	持续时间为6～72 h，发作次数≥3次，单关节炎
FMF家族史	＋

表1 儿童家族性地中海热的新诊断标准中的主要临床症状及其体征

临床症状	临床体征
发热	持续时间为6～72 h，体温>38 ℃，发作次数≥3次
腹痛	持续时间为6～72 h，发作次数≥3次
胸痛	持续时间为6～72 h，发作次数≥3次
关节炎	持续时间为6～72 h，发作次数≥3次，单关节炎
FMF家族史	＋

表2 不同年龄家族性地中海热患者接受秋水仙碱治疗的剂量(±s)

年龄组(岁)	秋水仙碱剂量
年龄组(岁)	体重[mg/(kg·d)]	体表面积[mg/(m²·d)]
<5	0.05±0.02	1.46±0.41
≥5～10	0.03±0.01	1.19±0.30
≥10～15	0.027±0.01	0.84±0.20
≥15～20	0.02±0.00	0.02±0.00

表2 不同年龄家族性地中海热患者接受秋水仙碱治疗的剂量(±s)

年龄组(岁)	秋水仙碱剂量
年龄组(岁)	体重[mg/(kg·d)]	体表面积[mg/(m²·d)]
<5	0.05±0.02	1.46±0.41
≥5～10	0.03±0.01	1.19±0.30
≥10～15	0.027±0.01	0.84±0.20
≥15～20	0.02±0.00	0.02±0.00

[1]	李成荣. 自身炎症性疾病[J]. 中华儿科杂志，2008, 46(11): 842-847.
[2]	Kelley RI, Takada I. Hereditary periodic fever[J]. N Engl J Med, 2002, 346(18): 1415-1416.
[3]	沈敏. 自身炎症性疾病和自身免疫病[J]. 中华临床免疫和变态反应杂志，2014, 8(4): 322-328.
[4]	Better OS, Zemer D. Familial Mediterranean fever[J]. Dtsch Med Wochenschr, 1991, 116(14): 548-552.
[5]	Ates İ, Akca Ö, Bülbü İ, et al. Case of familial mediterranean fever presenting with constant abdominal pain[J]. Reumatol Clín, 2016, 12(5): 299-300.
[6]	Mansfield E, Chae JJ, Komarow HD, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments[J]. Blood, 2001, 98(3): 851-859.
[7]	Tomiyama N, Higashiuesato Y, Oda T, et al. MEFV mutation analysis of familial Mediterranean fever in Japan[J]. Clin Exp Rheumatol, 2008, 26(1): 13-17.
[8]	Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1 beta production[J]. Proc Natl Acad Sci USA, 2006, 103(26): 9982-9987.
[9]	Peces R, Afonso S, Peces C, et al. Living kidney transplantation between brothers with unrecognized renal amyloidosis as the first manifestation of familial Mediterranean fever: a case report[J]. BMC Med Genet, 2017, 18(1): 97.
[10]	Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single center experience[J]. Rheumatol Int, 2018, 38(1): 67-74.
[11]	Heller H, Gafni J, Michaeli D, et al. The arthritis of familial Mediterranean fever (FMF)[J]. Arthritis Rheum, 1966, 9(1): 1-17.
[12]	Tunca M, Akar S, Onen F et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study[J]. Medicine (Baltimore), 2005, 84(1): 1-11.
[13]	Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever[J]. Semin Arthritis Rheum, 1996, 26(3): 612-627.
[14]	Soriano A, Manna R. Familial Mediterranean fever: new phenotypes[J]. Autoimmun Rev, 2012, 12(1): 31-37.
[15]	Papadopoulos VP, Giaglis S, Mitroulis I, et al. The population genetics of Familial Mediterranean fever: a Meta-analysis study[J]. Ann Hum Genet, 2008, 72(Pt 6): 752-761.
[16]	Ozalkaya E, Mir S, Sozeri B, et al. Familial Mediterranean fever gene mutation frequencies and genotype-phenotype correlations in the Aegean region of Turkey[J]. Rheumatol Int, 2011, 31(6): 779-784.
[17]	Habahbeh L, Hiary MA, Zaben SF, et al. Genetic profile of patients with familial Mediterranean fever (FMF): single center experience at King Hussein Medical Center (KHMC)[J]. Med Arch, 2015, 69(6): 417-420.
[18]	Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements[J]. Neth J Med, 2007, 65(9): 318-324.
[19]	Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations[J]. Eur J Hum Genet, 2001, 9(7): 473-483.
[20]	韩丽芳，蔡军伟，颜亮，等. 中国人群MEFV基因多态性研究[J]. 实用医学杂志，2006, 22(11): 1234-1235.
[21]	Berkun Y, Eisenstein EM. Diagnostic criteria of familial Mediterranean fever[J]. Autoimmun Rev, 2014, 13(4-5): 388-390.
[22]	Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood[J]. Rheumatology (Oxford), 2009, 48(4): 395-398.
[23]	Özçakar ZB, Yalçınkaya F, Çakar N, et al. Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF[J]. Eur J Pediatr, 2011, 170(8): 1055-1057.
[24]	Kondi A, Hentgen V, Piram M, et al. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders[J]. Rheumatology (Oxford), 2010, 49(11): 2200-2203.
[25]	Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever[J]. J Pediatr, 2012, 161(6): 1142-1146.
[26]	Cerquaglia C, Diaco M, Nucera G, et al. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update[J]. Curr Drug Targets Inflamm Allergy, 2005, 4(1): 117-124.
[27]	Ozkaya N, Yalçinkaya F. Colchicine treatment in children with familial Mediterranean fever[J]. Clin Rheumatol, 2003, 22(4-5): 314-317.
[28]	Amital H, Ben-Chetrit E. Therapeutic approaches to familial Mediterranean fever. What do we know and where are we going to？[J]. Clin Exp Rheumatol, 2004, 22(4 Suppl 34): S4-S7.
[29]	Grossman C, Farberov I, Feld O, et al. Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine[J]. Rheumatol Int, 2019, 39(3): 517-523.

[1]	张璇, 马宇童, 苗玉倩, 张云, 吴士文, 党晓楚, 陈颖颖, 钟兆明, 王雪娟, 胡淼, 孙岩峰, 马秀珠, 吕发勤, 寇海燕. 超声对Duchenne肌营养不良儿童膈肌功能的评价[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1068-1073.
[2]	张宝富, 俞劲, 叶菁菁, 俞建根, 马晓辉, 刘喜旺. 先天性原发隔异位型肺静脉异位引流的超声心动图诊断[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1074-1080.
[3]	韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[4]	刘婷婷, 林妍冰, 汪珊, 陈幕荣, 唐子鉴, 代东伶, 夏焙. 超声衰减参数成像评价儿童代谢相关脂肪性肝病的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 787-794.
[5]	周钰菡, 肖欢, 唐毅, 杨春江, 周娟, 朱丽容, 徐娟, 牟芳婷. 超声对儿童髋关节暂时性滑膜炎的诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 795-800.
[6]	米洁, 陈晨, 李佳玲, 裴海娜, 张恒博, 李飞, 李东杰. 儿童头面部外伤特点分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 511-515.
[7]	中华医学会烧伤外科学分会小儿烧伤学组. 儿童烧伤早期休克液体复苏专家共识(2023版)[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 371-376.
[8]	陆闻青, 陈昕怡, 任雪飞. 遗传代谢病儿童肝移植受者术后生活质量调查研究[J]. 中华移植杂志(电子版), 2023, 17(05): 287-292.
[9]	王蕾, 王少华, 牛海珍, 尹腾飞. 儿童腹股沟疝围手术期风险预警干预[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 768-772.
[10]	李芳, 许瑞, 李洋洋, 石秀全. 循证医学理念在儿童腹股沟疝患者中的应用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 782-786.
[11]	闵筱兰, 周洁超, 陈振添. 健康管理联合心理干预用于腹腔镜腹股沟疝手术患儿术后效果观察[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(05): 657-661.
[12]	吕垒, 冯啸, 何凯明, 曾凯宁, 杨卿, 吕海金, 易慧敏, 易述红, 杨扬, 傅斌生. 改良金氏评分在儿童肝豆状核变性急性肝衰竭肝移植手术时机评估中价值并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 661-668.
[13]	卓少宏, 林秀玲, 周翠梅, 熊卫莲, 马兴灶. CD64指数、SAA/CRP、PCT联合检测在小儿消化道感染性疾病鉴别诊断中的应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 505-509.
[14]	刘笑笑, 张小杉, 刘群, 马岚, 段莎莎, 施依璐, 张敏洁, 王雅晳. 中国学龄前儿童先天性心脏病流行病学研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1021-1024.
[15]	李静, 张玲玲, 邢伟. 兴趣诱导理念用于小儿手术麻醉诱导前的价值及其对家属满意度的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 812-817.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Current research status of familial Mediterranean fever

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Current research status of familial Mediterranean fever